Cargando…
Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability
BACKGROUND: Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutinib is that it predisposes patients to development of atrial fibrillation. OBJECTIVES: The purpose of this study...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352262/ https://www.ncbi.nlm.nih.gov/pubmed/34396309 http://dx.doi.org/10.1016/j.jaccao.2021.01.009 |